| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(10)70247-3 |
| P698 | PubMed publication ID | 21071270 |
| P50 | author | Dietmar Tamandl | Q73715222 |
| P2093 | author name string | Klaus Kaczirek | |
| Birgit Gruenberger | |||
| Thomas Gruenberger | |||
| Fritz Wrba | |||
| Johannes Schueller | |||
| Rudolf Roka | |||
| Sandra Freimann-Pircher | |||
| Ute Heubrandtner | |||
| P2860 | cites work | Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001 | Q24651526 |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study | Q33341477 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer | Q33372640 | ||
| Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study | Q33383423 | ||
| Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States | Q33949931 | ||
| Cholangiocarcinoma. | Q33990595 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials | Q34576456 | ||
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial | Q34614245 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| The epidemiology of cholangiocarcinoma | Q35802314 | ||
| A review and update on cholangiocarcinoma | Q35817693 | ||
| Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial | Q37400515 | ||
| Molecular targeted therapy of biliary tract cancer--results of the first clinical studies | Q37730110 | ||
| Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line | Q40742867 | ||
| Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver | Q43086184 | ||
| Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study | Q43237133 | ||
| Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial | Q43261590 | ||
| Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma | Q44529260 | ||
| EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases | Q45025171 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer | Q46687121 | ||
| A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer | Q46941755 | ||
| Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. | Q52935096 | ||
| Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma | Q64044533 | ||
| Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators | Q71848697 | ||
| Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer | Q77321354 | ||
| Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct | Q77861876 | ||
| P433 | issue | 12 | |
| P921 | main subject | cetuximab | Q420296 |
| oxaliplatin | Q422327 | ||
| ??? | Q18556397 | ||
| P304 | page(s) | 1142-1148 | |
| P577 | publication date | 2010-11-09 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study | |
| P478 | volume | 11 |
| Q48126437 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer |
| Q84325484 | A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management |
| Q33419175 | A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). |
| Q42130772 | A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma |
| Q37719383 | A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. |
| Q37639577 | A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers |
| Q45903506 | A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. |
| Q41652822 | A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study |
| Q37225342 | AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines |
| Q39025911 | Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States |
| Q39673531 | Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference |
| Q26822703 | Advances in systemic therapy for advanced pancreatobiliary malignancies |
| Q38082318 | Advances in the management of biliary tract cancers |
| Q89887782 | Applied precision cancer medicine in metastatic biliary tract cancer |
| Q57151552 | BINGO: targeted therapy for advanced biliary-tract cancer |
| Q35058487 | Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma |
| Q39289707 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications |
| Q82711651 | Biliary cancers, chemotherapy, and cetuximab |
| Q38017118 | Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options |
| Q33977171 | Chemotherapy and targeted therapy for gall bladder cancer |
| Q51340875 | Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. |
| Q37983498 | Chemotherapy for the biliary tract cancers: moving toward improved survival time |
| Q35715498 | Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. |
| Q36962011 | Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives |
| Q34775386 | Clinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma |
| Q38445683 | Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology |
| Q38001351 | Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part II: multidisciplinary management |
| Q39453572 | Current biologics for treatment of biliary tract cancers |
| Q57154668 | Current state of nonsurgical therapies for cholangiocarcinoma |
| Q37138732 | Current status of chemotherapy for the treatment of advanced biliary tract cancer |
| Q37505379 | Current status of immunotherapy for the treatment of biliary tract cancer |
| Q37161293 | Current therapy and future directions in biliary tract malignancies |
| Q37833005 | Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities |
| Q55381085 | EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs. |
| Q33436600 | Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis |
| Q51327505 | Emerging drugs for biliary cancer. |
| Q38642455 | Emerging molecular targets and therapy for cholangiocarcinoma |
| Q42220109 | Epstein-Barr virus-associated lymphoepithelioma-like cholangiocarcinoma: a rare variant of intrahepatic cholangiocarcinoma with favourable outcome. |
| Q38707983 | Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma |
| Q35840582 | Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma |
| Q90138085 | FOLFIRI as second-line treatment of metastatic biliary tract cancer patients |
| Q26784174 | Gallbladder Cancer in the 21st Century |
| Q35924976 | Gallbladder cancer: expert consensus statement. |
| Q35871195 | Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review |
| Q30317428 | Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. |
| Q53393758 | Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. |
| Q53347236 | Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma. |
| Q37955222 | Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. |
| Q37017110 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design |
| Q39137066 | Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. |
| Q38163597 | Hepatocellular carcinoma and cholangiocarcinoma: an update |
| Q37341081 | High Uptake of FDG Along a Biliary Stent |
| Q38703148 | Immunotherapeutic Approaches to Biliary Cancer |
| Q38686339 | Immunotherapy of biliary tract cancer |
| Q31145431 | Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma |
| Q48327823 | Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. |
| Q39186928 | Intrahepatic cholangiocarcinoma: current management and emerging therapies |
| Q27002547 | Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies |
| Q100316284 | Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation |
| Q28273788 | Management of perihilar cholangiocarcinoma in the era of multimodal therapy |
| Q36786161 | Metal stents: a bridge to surgery in hilar cholangiocarcinoma |
| Q35150642 | Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer |
| Q35820533 | Molecular Targets in Biliary Carcinogenesis and Implications for Therapy |
| Q38130469 | Multidisciplinary approaches to intrahepatic cholangiocarcinoma |
| Q37288576 | Multidisciplinary collaboration in gallbladder carcinoma treatment: A case report and literature review |
| Q38619219 | New Horizons for Precision Medicine in Biliary Tract Cancers |
| Q38160836 | New and emerging treatment options for biliary tract cancer |
| Q54476966 | New molecular and immunotherapeutic approaches in biliary cancer. |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q57224823 | Older adults with biliary tract cancer: treatment and prognosis |
| Q27010873 | Optimum chemotherapy for the management of advanced biliary tract cancer |
| Q45027102 | Outcomes in unresectable and locally advanced resected cholangiocarcinoma |
| Q36545534 | PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA |
| Q40352514 | Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). |
| Q36224475 | Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis |
| Q39647813 | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer |
| Q33994406 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. |
| Q48203761 | Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. |
| Q53063502 | Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib. |
| Q27016150 | Progression of targeted therapy in advanced cholangiocarcinoma |
| Q35000796 | Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers |
| Q37997942 | Role of chemotherapy in treatments for biliary tract cancer. |
| Q38955578 | Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. |
| Q28550991 | Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q50526996 | Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. |
| Q36336456 | Synchronous double primary cancer - intrahepatic cholangiocarcinoma with bone metastases and thyroid carcinoma: A case report |
| Q34551877 | Systemic Therapy of Cholangiocarcinoma |
| Q93140863 | Systemic therapy for cholangiocarcinoma |
| Q40686537 | TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer |
| Q64249982 | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| Q26798443 | Targeted Therapy in Biliary Tract Cancers |
| Q37584590 | Targeted agents: how can we improve the outcome in biliary tract cancer? |
| Q37132750 | Targeted therapy for biliary tract cancer |
| Q37982650 | Targeted therapy for biliary tract cancers |
| Q33608594 | Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy |
| Q47139810 | The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis |
| Q26751224 | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets |
| Q41988283 | The value of molecular biomarkers in biliary tract cancer in the era of targeted therapy. |
| Q57074642 | Therapie des metastasierten Cholangiokarzinoms |
| Q35179917 | Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer |
| Q36038456 | Trial watch: Chemotherapy with immunogenic cell death inducers |
| Q35854505 | Tumors of ampulla of Vater: A case series and review of chemotherapy options |
| Q38183813 | Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy |
| Q57112202 | [Treatment approach for gall bladder and extrahepatic bile duct cancer] |
Search more.